natgillin/translations-raw huggingface dataset:
The aqueous pharmaceutical suspension according to claim 7, wherein the sweetener system comprises, by weight/volume (g/100 mL), about 20% of sucrose and about 10% of xylitol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav sladila sadrži, težinski/volumno (g/100 ml), otprilike 20 % saharoze i otprilike 10 % ksilitola.
The aqueous pharmaceutical suspension according to claim 7, the ratio of the amount of (sucrose or invert sucrose): (xylitol, sorbitol or sorbitol solution, or maltitol solution) is about 1:1 to 2:1. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što odnos količina (saharoza ili invertna saharoza)/(ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola) je otprilike 1:1 do 2:1.
The aqueous pharmaceutical suspension according to claim 7, the ratio of the amount of (sucrose or invert sucrose): (xylitol, sorbitol or sorbitol solution, or maltitol solution) is about 2:1. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što odnos količina (saharoza ili invertna saharoza)/(ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola) je otprilike 2:1.
The aqueous pharmaceutical suspension according to claim 7, wherein the butylparaben, or sodium butylparaben is, by weight/volume (g/100 mL), about 0.0008% to about 0.0240%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što butilparaben ili natrij-butilparaben iznosi, težinski/volumno (g/100 ml), otprilike 0,0008 % do otprilike 0,0240 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the edetate disodium is, by weight/volume (g/100 mL), about 0.12% to about 0.18%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što dinatrijev edetat iznosi, težinski/volumno (g/100 ml), otprilike 0,12 % do otprilike 0,18 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the preservative system comprises propylparaben, butylparaben and edetate disodium. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav konzervansa sadrži propilparaben, butilparaben i dinatrijev edetat.
The aqueous pharmaceutical suspension according to claim 7, wherein the sorbic acid or potassium sorbate is, by weight/volume (g/100 mL), about 0.12% to about 0.20%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sorbinska kiselina ili kalijev sorbat iznosi, težinski/volumno (g/100 ml), otprilike 0,12 % do otprilike 0,20 %.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100 mL), about 0.65% to about 0.87% of sodium phosphate monobasic or a corresponding equivalent amount of a sodium phosphate monobasic hydrate, or about 0:74% to about 0.99% of potassium phosphate monobasic; and about 0.32% to about 0.67% of sodium phosphate dibasic or a corresponding equivalent amount of a sodium phosphate dibasic hydrate, or about 0.39% to about 0.82% of potassium phosphate dibasic or a corresponding equivalent amount of a potassium phosphate dibasic hydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinski/volumno (g/100 ml), otprilike 0,65 % do otprilike 0,87 % jednobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu jednobaznog natrijevog fosfata hidrata, ili otprilike 0,74 % do otprilike 0,99 % jednobaznog kalijevog fosfata; i otprilike 0,32 % do otprilike 0,67 % dvobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu dvobaznog natrijevog fosfata hidrata, ili otprilike 0,39 % do otprilike 0,82 % dvobaznog kalijevog fosfata ili odgovarajuću ekvivalentnu količinu dvobaznog kalijevog fosfata hidrata.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100 mL), about 0.06% to about 1.05% of sodium phosphate monobasic or a corresponding equivalent amount of a sodium phosphate monobasic hydrate; and about 0.32% to about 2.69% of sodium phosphate dibasic or a corresponding equivalent amount of sodium phosphate dibasic hydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinski/volumno (g/100 ml), otprilike 0,06 % do otprilike 1,05 % jednobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu jednobaznog natrijevog fosfata hidrata; i otprilike 0,32 % do otprilike 2,69 % dvobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu dvobaznog natrijevog fosfata hidrata.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100 mL), about 0.65% to about 0.87% of sodium phosphate monobasic or a corresponding equivalent amount of a sodium phosphate monobasic hydrate; and about 0.32% to about 0.67% of sodium phosphate dibasic or a corresponding equivalent amount of a sodium phosphate dibasic hydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinski/volumno (g/100 ml), otprilike 0,65 % do otprilike 0,87 % jednobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu jednobaznog natrijevog fosfata hidrata; i otprilike 0,32 % do otprilike 0,67 % dvobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu dvobaznog natrijevog fosfata hidrata.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100 mL), about 0.75% to about 1.00% of sodium phosphate monobasic monohydrate, and about 0.60% to about 1.25% of sodium phosphate dibasic heptahydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinski/volumno (g/100 ml), otprilike 0,75 % do otprilike 1,00 % jednobaznog natrijevog fosfata monohidrata, te otprilike 0,60 % do otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata.
The aqueous pharmaceutical suspension according to claims 7, optionally further comprising, by weight/volume (g/100 mL), 0% to about 0.50% of an opacifying agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), 0 % do otprilike 0,50 % sredstva za zamućivanje.
The aqueous pharmaceutical suspension according to claim 7, optionally further comprising, by weight/volume (g/100 mL), 0% to about 0.10% of an opacifying agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), 0 % do otprilike 0,10 % sredstva za zamućivanje.
The aqueous pharmaceutical suspension according to claim 7, optionally further comprising, by weight/volume (g/100mL), about 0.05% to about 0.10% of an opacifying agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,05 % do otprilike 0,10 % sredstva za zamućivanje.
The aqueous pharmaceutical suspension according to clam 71, wherein the opacifying agent is titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 71, naznačena time što sredstvo za zamućivanje je titanijev dioksid.
The aqueous pharmaceutical suspension according to claim 73, wherein the opacifying agent is Titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 73, naznačena time što sredstvo za zamućivanje je titanijev dioksid.
The aqueous pharmaceutical suspension according to claim 7, optionally further comprising, by weight/volume (g/100 mL), about 0.40% to about 0.45% of a flavoring agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,40 % do otprilike 0,45 % sredstva za aromatiziranje.
The aqueous pharmaceutical suspension according to claim 7, comprising, by weight/volume (g/100 mL), about 0.60% of fexofenadine zwitterionic dihydrate Form I, about 2.5% of propylene glycol, about 0.15% of edetate disodium, about 0.034% of propylparaben, about 0.017% of butylparaben, about 0.35% of xanthan gum, about 0.05% of Poloxamer 407, about 1.25% of sodium phosphate dibasic heptahydrate, about 0.75% of sodium phosphate monobasic monohydrate, about 10% of sucrose, and about 10% of xylitol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sadrži, težinski/volumno (g/100 ml), otprilike 0,60 % dvojnoionskog dihidratnog Oblika I feksofenadina, otprilike 2,5 % propilen-glikola, otprilike 0,15 % dinatrijevog edetata, otprilike 0,034 % propilparabena, otprilike 0,017 % butilparabena, otprilike 0,35 % ksantanske gume, otprilike 0,05 % Poloksamera 407, otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata, otprilike 0,75 % jednobaznog natrijevog fosfata monohidrata, otprilike 10 % saharoze, te otprilike 10 % ksilitola.
The aqueous pharmaceutical suspension according to claim 86, optionally further comprising, by weight/volume (g/100 mL), about 0.1% of titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 86, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,1 % titanijevog dioksida.
The aqueous pharmaceutical suspension according to claim 87, optionally further comprising, by weight/volume (g/100 mL), about 0.4% of raspberry cream flavor. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 87, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,4 % arome kreme od malina.
The aqueous pharmaceutical, suspension according to claim 7, comprising, by weight/volume (g/100 mL), about 0.60% of fexofenadine zwitterionic dihydrate Form I, about 2.5% of propylene glycol, about 0.15% of edetate disodium, about 0.034% of propylparaben, about 0.017% of butylparaben, about 0.35% of xanthan gum, about 0.05% of Poloxamer 407, about 1.25% of sodium phosphate dibasic heptahydrate, about 0.75% of sodium phosphate monobasic monohydrate, about 20% of sucrose, and about 10% of sorbitol solutions The aqueous pharmaceutical suspension according to claim 89, further comprising, by weight/volume-(g/100 mL); about 0.1% of titanium dioxide. 
Vodena farmaceutska, suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sadrži, težinski/volumno (g/100 ml), otprilike 0,60 % dvojnoionskog dihidratnog Oblika I feksofenadina, otprilike 2,5 % propilen-glikola, otprilike 0,15 % dinatrijevog edetata, otprilike 0,034 % propilparabena, otprilike 0,017 % butilparabena, otprilike 0,35 % ksantanske gume, otprilike 0,05 % Poloksamera 407, otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata, otprilike 0,75 % jednobaznog natrijevog fosfata monohidrata, otprilike 20 % saharoze, te otprilike 10 % otopina sorbitola. Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 89, naznačena time što dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,1 % titanijevog dioksida.
The aqueous pharmaceutical suspension according to claim 1, comprising, by weight/volume (g/100 mL), about 0.60% of fexofenadine zwitterionic dihydrate Form I, about 2.5% of propylene glycol, about 0.042% of propylparaben, about 0.021% of butylparaben; about 0.35% of xanthan gum, about 0.05% of Poloxamer 407, about 1.25% of sodium phosphate dibasic heptahydrate, about 0.75% of sodium phosphate monobasic monohydrate, about 20% of sucrose, and about 10% of xylitol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što sadrži, težinski/volumno (g/100 ml), otprilike 0,60 % dvojnoionskog dihidratnog Oblika I feksofenadina, otprilike 2,5 % propilen-glikola, otprilike 0,042 % propilparabena, otprilike 0,021 % butilparabena; otprilike 0,35 % ksantanske gume, otprilike 0,05 % Poloksamera 407, otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata, otprilike 0,75 % jednobaznog natrijevog fosfata monohidrata, otprilike 20 % saharoze, te otprilike 10 % ksilitola.
Cy1 is selected from: 
Cy1 je izabran od slijedećih:
is selected from phenyl, or a 5-6 membered heterocyclyl or heteroaryl ring, provided that: 
je izabran iz grupe koju čine fenil, ili 5-6 -člani heterociklil ili heteroaril prsten, uz uvjet da:
when Cy1 is phenyl substituted in the meta position with W then: 
kada je Cy1 jednako fenil supstituiran u meta položaju sa W tada:
when Cy1 is phenyl substituted in the para position with W, and R1, R2, R3, and R4 are each hydrogen then 
kada je Cy1 fenil supstituiran u para položaju sa W, i svako R1, R2, R3 i R4 je vodik tada:
W is selected from: 
W je izabran od:
The compound of claim 1, wherein Cy1 is optionally substituted thienyl and compounds have the structure: 
Spoj prema patentnom zahtjevu 1, naznačen time što je Cy1 izborno supstituirani tienil i spojevi imaju strukturu:
W is selected from: 
W je izabran od slijedećih:
A compound or a pharmaceutically acceptable salt according to any of claims 1 to 8 or pharmaceutical composition thereof, for use in treating an inflammatory or immune-related physiological disorder, symptom or disease in a patient in need of such treatment. 
Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 18 ili njegova farmaceutska kompozicija, naznačena time, što se koristi za primjenu u liječenju inflamatornog ili fiziološkog poremaćaja, simptoma ili bolesti povezanog sa imunološkim sustavom kod pacijenta kod kojeg postoji potreba za takvim tretmanom.
The compound according to claim 21, where the inflammatory disease is rheumatoid arthritis, asthma, psoriasis, chronic obstructive pulmonary disease, inflammatory bowel disease or multiple sclerosis. 
Spoj prema patentnom zahtjevu 21, naznačen time što je inflamatorna bolest reumatoidni artritis, astma, psolrijaza, kronična opstruktivna bolest pluća, inflamatorna bolest crijeva ili multipla skleroza.
Use of a compound or a pharmaceutically acceptable salt according to any of claims 1 to 8 or a pharmaceutical composition thereof in the manufacture of a medicament for treating an inflammatory or immune-related physiological disorder, symptom or disease. 
Primjena spojeva ili farmaceutski prihvatljive soli prema bilo kojem od patentnih zahtjeva 1 do 18 ili njegove farmaceutske kompozicije, naznačena time što se koristi u proizvodnji lijeka za liječenje inflamatornog ili fiziološkog poremećaja, simptoma ili bolesti povezanih sa imunološkim sustavom.
C1-8alkenyl denotes a straight chain, branched, or cyclic hydrocarbon group having from 1 to 8 carbon atoms and at least one double bond; 
-8alkenil označava ugljikovodičnu skupinu ravnog lanca, razgranatu ili cikličku koja ima 1 do 8 atoma ugljika i barem jednu dvostruku vezu;
A composition according to claim 1, wherein said selective 5HT-2C receptor agonist is selected from the following compounds and pharmaceutically acceptable salts, solvates, and hydrates thereof: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da je navedeni selektivni agonist 5HT-2C receptora izabran iz skupine koju čine slijedeći spojevi i njihove farmaceutski prihvatljive soli, solvati i hidrati:
A composition according to claim 1, wherein said selective 5HT-2C receptor agonist is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da navedeni selektivni agonist 5HT-2C receptora je (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin ili njegova farmaceutski prihvatljiva sol, solvat i hidrat.
The composition according to any one of claims 1 to 25 or the composition for use according to any one of claims 26 to 33, wherein the amount of phentermine alone and the amount of selective 5-HT2C agonist alone are therapeutically sub-effective in decreasing food intake in a mammal. 
Pripravak u skladu s bilo kojim zahtjevom 1 do 25 ili uporaba pripravka u skladu s bilo kojim zahtjevom 26 do 33, naznačen time, da je količina samog fentermina i količina samog selektivnog 5-HT2C agonista terapeutski sub-učinkovita u smanjivanju uzimanja hrane kod sisavca.
The pharmaceutical composition of claim 10, wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor. 
Farmaceutska kompozicija prema patentnom zahtjevu 11, naznačena time što je HCV antivirusno sredstvo - antivirusno sredstvo izabrano iz grupe koju čine inhibitor HCV proteaze i inhibitor HCV NS5B polimeraze.
The process of claim 1, wherein the phosphoric acid and 1-halo-3,5-dimethyladamantane are present in a phosphoric acid:1-halo-3,5-dimethyladamantane mole ratio within a range of 2:1 to 4:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što fosforna kiselina i 1-halogen-3,5-dimetiladamantan dolaze u odnosu fosforna kiselina/1-halogen-3,5-dimetiladamantan od 2:1 do 4:1.
The process of claim 5, wherein the sufficient period of time is 1 to 10 hours. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što dovoljno dugo vrijeme je 1 do 10 sati.
The process of claim 1, wherein the nitrile is selected from the group consisting of propionitrile, butyronitrile, valeronitrile, phenylacetonitrile, and acetonitrile. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što nitril se bira iz skupine koju čine propionitril, butironitril, valeronitril, fenilacetonitril i acetonitril.
The process of claim 1, wherein the nitrile is present in an amount of 2 to 15 moles/mol of1-halo-3,5-dimethyladamantane. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što nitril dolazi u količini od 2 do 15 mol na 1 mol 1-halogen-3,5-dimetiladamantana.
The process of claim 9, wherein the nitrile is present in an amount of 3 to 6 moles/mole of 1-halo-3,5-dimethyladamantane. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što nitril dolazi u količini od 3 do 6 mol na 1 mol 1-halogen-3,5-dimetiladamantana.
A process for the preparation ofmemantine hydrochloride, comprising: reacting 1-halo-3,5-dimethyladamantane and a nitrile in the presence of phosphoric acid at a temperature of 50° to 100°C for a sufficient period of time to obtain n-acetamido-3,5-dimethyladamantane; and converting the n-acetamido-3,5-dimethyladamantane to memantine hydrochloride. 
Postupak dobivanja memantin-hidroklorida, naznačen time što se sastoji u: reakciji 1-halogen-3,5-dimetiladamantana s nitrilom, u prisutnosti fosforne kiseline, na temperaturi od 50 °C do 100 °C, kroz dovoljno dugo vrijeme da se dobije n-acetamido-3,5-dimetiladamantan; te u prevođenju n-acetamido-3,5-dimetiladamantana u memantin-hidroklorid.
reacting 1-halo-3,5-dimethyladamantane and a nitrile in the presence of phosphoric acid at a temperature of 50° to 100°C for a sufficient period of time to obtain n-acetamido-3,5-dimethyladamantane; 
reakciji 1-halogen-3,5-dimetiladamantana s nitrilom, u prisutnosti fosforne kiseline, na temperaturi od 50 °C do 100 °C, kroz dovoljno dugo vrijeme da se dobije n-acetamido-3,5-dimetiladamantan;
dissolving n-acetamido-3,5-dimethyladamantane in a solvent selected from the group consisting of C3-6 alcohols in the presence of a strong inorganic base for a sufficient period of time to obtain 1-amino-3,5-dimethyladamantane; and 
otapanju n-acetamido-3,5-dimetiladamantana u otapalu koje se bira iz skupine koju čine C3-6 alkoholi, u prisutnosti jake anorganske baze, kroz dovoljno dugo vrijeme da se dobije 1-amino-3,5-dimetiladamantan; i
represents methyl or ethyl, and 
predstavlja metil ili etil, a
A process according to claim 1, wherein R3 and R4 taken together with the nitrogen atom to which they are bound represent a morpholin-4-yl residue. 
Postupak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što R3 i R4, uzeti zajedno s atomom dušika na kojeg su vezani, predstavljaju morfolin-4-ilni ostatak.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-a i IL-1.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
Use according to claim 35, wherein inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, inflammatory bowel conditions, Crohn's disease, bronchitis, and cystic fibrosis. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis, te cistična fibroza.
Use according to claim 35, wherein said inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel conditions, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, coronary infarct damage, chronic inflammation, endotoxin shock, and smooth muscle proliferation disorders. 
Upotreba spoja u skladu s patentnim zahtjevom 35, gdje upalna stanja i imunosne poremećaje se bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, egzem, dermatitis, infarktno oštećenje koronarnih žila, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with excessive unregulated production of cytokines or inflammatory mediators. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje bolesti, poremećaja i stanja, naznačena time, ili povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
A compound selected from compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: 
spoj izabran među spojevima Formule (Ia) i njihovim farmaceutski prihvatljivim solima, solvatima i hidratima:
is a group of Formula (A): wherein: 
je skupina Formule (A):
A compound according to claim 1, selected from compounds having Formula (IIa) and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da je spoj izabran među spojevima koji imaju Formulu (IIa) i njihovim farmaceutski prihvatljivim solima, solvatima i hidratima: